Musculoskeletal
injuries are on the rise. First-line management of such
injuries usually employs the RICE (rest,
ice, compression, and elevation) approach to limit excessive
inflammation. Nonsteroidal anti-inflammatory drugs (
NSAIDs) are also commonly used to limit
inflammation and to control
pain.
Traumeel(®), a preparation with bioregulatory effects is also used to treat the symptoms associated with acute musculoskeletal
injuries, including
pain and swelling.
Traumeel is a fixed combination of
biological and
mineral extracts, which aims to apply stimuli to multiple targets to restore normal functioning of regulatory mechanisms. This paper presents the accumulating evidence of
Traumeel's action on the inflammatory process, and of its efficacy and tolerability in randomized trials, as well as observational and surveillance studies for the treatment of musculoskeletal
injuries.
Traumeel has shown comparable effectiveness to
NSAIDs in terms of reducing symptoms of
inflammation, accelerating recovery, and improving mobility, with a favorable safety profile. While continued research and development is ongoing to broaden the clinical evidence of
Traumeel in acute musculoskeletal injury and to further establish its benefits, current information suggests that
Traumeel may be considered as an
anti-inflammatory agent that is at least as effective and appears to be better tolerated than
NSAIDs.